M
Malcolm J. Moore
Researcher at Princess Margaret Cancer Centre
Publications - 238
Citations - 45832
Malcolm J. Moore is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 64, co-authored 231 publications receiving 42222 citations. Previous affiliations of Malcolm J. Moore include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
Charles S. Fuchs,S. Azevedo,Takuji Okusaka,J.-L. Van Laethem,Lara Lipton,Helen Riess,Cezary Szczylik,Malcolm J. Moore,Marc Peeters,G. Bodoky,Masataka Ikeda,Bohuslav Melichar,R. Nemecek,S. Ohkawa,A. Świeboda-Sadlej,Sergei Tjulandin,E. Van Cutsem,Robert D. Loberg,Vincent Haddad,J.L. Gansert,B.A. Bach,Alfredo Carrato +21 more
TL;DR: Ganitumab combined with gem citabine had manageable toxicity but did not improve OS, compared with gemcitabine alone in unselected patients with metastatic pancreatic cancer.
Journal ArticleDOI
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
Chris Verslype,E. Van Cutsem,Mario Dicato,Nadir Arber,Jordan Berlin,David Cunningham,A. de Gramont,Eduardo Díaz-Rubio,Michel Ducreux,Thomas Gruenberger,Daniel G. Haller,Karin Haustermans,Paulo M. Hoff,David J. Kerr,Roberto Labianca,Malcolm J. Moore,Bernard Nordlinger,Atsushi Ohtsu,Ph. Rougier,Werner Scheithauer,H.-J. Schmoll,Alberto Sobrero,Josep Tabernero,C.J.H. van de Velde +23 more
TL;DR: There is now robust evidence in favour of systemic therapy with sorafenib in patients with advanced HCC with preserved liver function, and those involved in the care for patients with HCC should be encouraged to participate in well-designed clinical trials, to increase evidence-based knowledge and to make further progress.
Journal ArticleDOI
Canadian consensus guidelines for the management of testicular germ cell cancer.
Lori Wood,Christian Kollmannsberger,Michael A.S. Jewett,Peter Chung,S.J. Hotte,Martin E. O’Malley,Joan Sweet,Lynn Anson-Cartwright,Eric Winquist,Scott North,Scott Tyldesley,Jeremy Sturgeon,Mary Gospodarowicz,Roanne J. Segal,Tina Cheng,Peter Venner,Malcolm J. Moore,Peter Albers,Robert Huddart,Craig R. Nichols,Padraig Warde +20 more
TL;DR: This Canadian Consensus Guideline covers many aspects of the diagnosis and management of germ cell cancer, and is of considerable importance that clear, comprehensive and up-to-date consensus guidelines are available.
Journal ArticleDOI
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
Paula N. Fishman,Gregory R. Pond,Malcolm J. Moore,Amit M. Oza,Ronald Burkes,Lillian L. Siu,Ronald Feld,Steven Gallinger,Paul D. Greig,Jennifer J. Knox +9 more
TL;DR: Prospective trials evaluating patient benefit are required to confirm this activity in adenocarcinoma of the small bowel using newer systemic therapies, until such time retrospective reviews such as this will continue to guide treatment decisions.
Journal ArticleDOI
Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
Lillian L. Siu,Jeremy Shapiro,Derek J. Jonker,Chris Karapetis,John Zalcberg,John Zalcberg,John Simes,Félix Couture,Malcolm J. Moore,Timothy J. Price,Jehan Siddiqui,Louise M. Nott,Danielle Charpentier,Winston Liauw,Michael B. Sawyer,Michael Jefford,Nadine M Magoski,Andrew Haydon,Ian Walters,Jolie Ringash,Dongsheng Tu,Christopher J. O'Callaghan +21 more
TL;DR: Despite positive effects on PFS and objective response, cetuximab plus brivanib increased toxicity and did not significantly improve OS in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal cancer.